Nestle

Last updated January 31, 2026

125

Innovation Areas

3,230

Inventors

Collaborations

Nut flour oral immunotherapy formulations: NestleRecent Research Landscape

Standardizing the ratio of multiple active proteins in liquid matrices is difficult due to varying degradation rates. Precise stoichiometric control ensures consistent immunological dosing and shelf stability for pediatric oral delivery.

What technical problems is Nestle addressing in Nut flour oral immunotherapy formulations?

Acute allergic symptom severity

(4)evidences

Uncontrolled physiological reactions to environmental allergens like Fel D1 cause significant respiratory distress and physical discomfort. Reducing these symptoms directly improves patient quality of life and prevents acute inflammatory complications.

Uncontrolled allergen dose variability

(4)evidences

Infant dietary limitations and inconsistent dosing formats prevent effective early-life immune modulation. Standardizing multi-allergen delivery in pediatric-friendly vehicles overcomes compliance and safety hurdles in desensitization.

Unmanaged allergen exposure risks

(2)evidences

Inconsistent dosing schedules lead to loss of desensitization or severe allergic reactions upon resumption. Standardizing protocols for missed doses prevents therapeutic failure and anaphylactic events.